QQQ   437.03 (+2.68%)
AAPL   183.60 (+0.70%)
MSFT   409.40 (+1.80%)
META   487.37 (+4.13%)
GOOGL   143.45 (+0.63%)
AMZN   173.77 (+3.07%)
TSLA   196.12 (+0.69%)
NVDA   774.71 (+14.82%)
NIO   5.77 (-3.35%)
AMD   182.59 (+11.14%)
BABA   76.21 (+0.83%)
T   16.65 (-2.06%)
F   12.19 (+0.41%)
MU   85.89 (+5.40%)
CGC   3.42 (-0.58%)
GE   152.05 (+2.00%)
DIS   107.89 (+0.20%)
AMC   4.40 (-3.72%)
PFE   27.51 (-0.58%)
PYPL   58.28 (+1.39%)
XOM   105.31 (+0.44%)
QQQ   437.03 (+2.68%)
AAPL   183.60 (+0.70%)
MSFT   409.40 (+1.80%)
META   487.37 (+4.13%)
GOOGL   143.45 (+0.63%)
AMZN   173.77 (+3.07%)
TSLA   196.12 (+0.69%)
NVDA   774.71 (+14.82%)
NIO   5.77 (-3.35%)
AMD   182.59 (+11.14%)
BABA   76.21 (+0.83%)
T   16.65 (-2.06%)
F   12.19 (+0.41%)
MU   85.89 (+5.40%)
CGC   3.42 (-0.58%)
GE   152.05 (+2.00%)
DIS   107.89 (+0.20%)
AMC   4.40 (-3.72%)
PFE   27.51 (-0.58%)
PYPL   58.28 (+1.39%)
XOM   105.31 (+0.44%)
QQQ   437.03 (+2.68%)
AAPL   183.60 (+0.70%)
MSFT   409.40 (+1.80%)
META   487.37 (+4.13%)
GOOGL   143.45 (+0.63%)
AMZN   173.77 (+3.07%)
TSLA   196.12 (+0.69%)
NVDA   774.71 (+14.82%)
NIO   5.77 (-3.35%)
AMD   182.59 (+11.14%)
BABA   76.21 (+0.83%)
T   16.65 (-2.06%)
F   12.19 (+0.41%)
MU   85.89 (+5.40%)
CGC   3.42 (-0.58%)
GE   152.05 (+2.00%)
DIS   107.89 (+0.20%)
AMC   4.40 (-3.72%)
PFE   27.51 (-0.58%)
PYPL   58.28 (+1.39%)
XOM   105.31 (+0.44%)
QQQ   437.03 (+2.68%)
AAPL   183.60 (+0.70%)
MSFT   409.40 (+1.80%)
META   487.37 (+4.13%)
GOOGL   143.45 (+0.63%)
AMZN   173.77 (+3.07%)
TSLA   196.12 (+0.69%)
NVDA   774.71 (+14.82%)
NIO   5.77 (-3.35%)
AMD   182.59 (+11.14%)
BABA   76.21 (+0.83%)
T   16.65 (-2.06%)
F   12.19 (+0.41%)
MU   85.89 (+5.40%)
CGC   3.42 (-0.58%)
GE   152.05 (+2.00%)
DIS   107.89 (+0.20%)
AMC   4.40 (-3.72%)
PFE   27.51 (-0.58%)
PYPL   58.28 (+1.39%)
XOM   105.31 (+0.44%)
NASDAQ:PMN

ProMIS Neurosciences (PMN) Stock Price, News & Analysis

$1.96
-0.21 (-9.68%)
(As of 12:52 PM ET)
Today's Range
$1.91
$2.28
50-Day Range
$0.97
$2.81
52-Week Range
$0.95
$8.95
Volume
70,509 shs
Average Volume
63,798 shs
Market Capitalization
$37.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

ProMIS Neurosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
291.4% Upside
$8.00 Price Target
Short Interest
Healthy
0.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($1.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

503rd out of 932 stocks

Pharmaceutical Preparations Industry

229th out of 427 stocks


PMN stock logo

About ProMIS Neurosciences Stock (NASDAQ:PMN)

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

PMN Stock Price History

PMN Stock News Headlines

ProMIS Neurosciences (NASDAQ:PMN) Shares Down 4.4%
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Closing Bell: Promis Neurosciences Inc up on Friday (PMN)
See More Headlines
Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
3/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PMN
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+308.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
($0.16) per share

Miscellaneous

Free Float
16,940,000
Market Cap
$37.02 million
Optionable
Not Optionable
Beta
0.71
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Eugene Williams (Age 65)
    Co-Founder & Chairman
    Comp: $439.21k
  • Mr. Neil K. Warma M.B.A. (Age 61)
    President, Interim CEO, Principal Executive Officer & Director
    Comp: $40k
  • Dr. Neil R. Cashman M.D. (Age 72)
    Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
    Comp: $333.8k
  • Mr. Gavin T. Malenfant (Age 60)
    Chief Operating Officer
    Comp: $413.49k
  • Mr. Daniel E. Geffken M.B.A. (Age 67)
    Chief Financial Officer
    Comp: $90.81k
  • Dr. Johanne Kaplan Ph.D. (Age 64)
    Chief Development Officer
    Comp: $265.47k
  • Dr. Ernest D. Bush Ph.D.
    Head of Pharmacology/Toxicology & Senior Consultant
  • Dr. David Wishart Ph.D.
    Chief Physics Officer
  • Mr. Dennis Chen Ph.D.
    Head of Manufacturing & Senior Consultant
  • Dr. Larry Douglas Altstiel M.D. (Age 74)
    Ph.D., Chief Medical Officer














PMN Stock Analysis - Frequently Asked Questions

Should I buy or sell ProMIS Neurosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PMN shares.
View PMN analyst ratings
or view top-rated stocks.

What is ProMIS Neurosciences' stock price target for 2024?

2 brokers have issued 12-month price targets for ProMIS Neurosciences' stock. Their PMN share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 291.4% from the stock's current price.
View analysts price targets for PMN
or view top-rated stocks among Wall Street analysts.

How have PMN shares performed in 2024?

ProMIS Neurosciences' stock was trading at $1.15 at the beginning of 2024. Since then, PMN stock has increased by 77.7% and is now trading at $2.0441.
View the best growth stocks for 2024 here
.

When is ProMIS Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our PMN earnings forecast
.

Who are ProMIS Neurosciences' major shareholders?

ProMIS Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ieq Capital LLC (0.16%).

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMN) was last updated on 2/22/2024 by MarketBeat.com Staff